Table 2.
Participant demographics, clinical measures and global brain measures for 22q11.nonASD compared with 22q11.ASD
| 22q11.nonASD | 22q11.ASD | Significance | ||||
|---|---|---|---|---|---|---|
| (n = 25 [11♂, 14♀]) | (n = 30 [16♂, 14♀]) | t | P | |||
| Age (years) | 15 ± 6 | (6–25) | 16 ± 7 | (6–31) | −0.635 | 0.528 |
| Full-scale IQ | 86 ± 15 | (60–116) | 82 ± 12 | (61–112) | 1.066 | 0.291 |
| ADI-R Sociala | 5 ± 4 | (1–9) | 19 ± 5 | (10–28) | −11.00 | <0.001* |
| ADI-R Communicationa | 6 ± 4 | (0–16) | 14 ± 4 | (8–24) | −6.027 | <0.001* |
| ADI-R Repetitivea | 1 ± 1 | (0–4) | 3 ± 3 | (0–12) | −3.481 | 0.001* |
| ADOS Communicationb | 2 ± 1 | (0–6) | 3 ± 2 | (0–6) | −4.253 | <0.001* |
| ADOS Socialb | 3 ± 2 | (0–8) | 7 ± 3 | (1–14) | −5.036 | <0.001* |
| ADOS Repetitiveb | 1 ± 1 | (0–2) | 1 ± 1 | (0–1) | −1.494 | 0.141 |
| SIPS Positivec | 4 ± 4 | (0–10) | 4 ± 4 | (0–16) | −0.304 | 0.763 |
| SIPS Negativec | 5 ± 4 | (0–18) | 6 ± 5 | (0–15) | −1.365 | 0.180 |
| SIPS Disorganizedc | 2 ± 2 | (0–8) | 3 ± 3 | (0–9) | −0.834 | 0.409 |
| SIPS Generalc | 3 ± 3 | (0–10) | 5 ± 3 | (0–12) | −1.265 | 0.213 |
| Psychotropic medication (none/antipsych/antidep/stimul) | 21/1/1/2 | 20/4/6/1 | ||||
| Total gray vol (L) | 0.60 ± 0.22 | (0.41–0.88) | 0.60 ± 0.22 | (0.59–0.80) | 0.148 | 0.883 |
| Average CT (mm) | 2.71 ± 0.17 | (2.45–3.06) | 2.73 ± 0.12 | (2.53–2.92) | −0.239 | 0.812 |
| Total SA (m2) | 0.20 ± 0.25 | (0.13–0.25) | 0.21 ± 0.18 | (0.17–0.24) | −0.883 | 0.381 |
Data expressed as mean ± standard deviation (range). aData based on 55 individuals. bData based on 53 individuals. cData based on 43 individuals. Medication: none, no medication; antipsych, antipsychotic medication; antidep, antidepressant medication; stimul, psychostimulant medication. *P < 0.05.